Objective response rate for all randomized patients
| Response . | BSC (n = 229) . | Tipifarnib (n = 228) . |
|---|---|---|
| Complete response | 0 | 18 (8%) |
| Partial response | 1 (< 1%) | 6 (3%) |
| Hematologic improvement | 2 (1%) | 14 (6%) |
| Stable disease | 130 (57%) | 105 (46%) |
| Progressive disease | 46 (20%) | 36 (16%) |
| Not done/not evaluable | 50 (22%) | 49 (21%) |
| Response . | BSC (n = 229) . | Tipifarnib (n = 228) . |
|---|---|---|
| Complete response | 0 | 18 (8%) |
| Partial response | 1 (< 1%) | 6 (3%) |
| Hematologic improvement | 2 (1%) | 14 (6%) |
| Stable disease | 130 (57%) | 105 (46%) |
| Progressive disease | 46 (20%) | 36 (16%) |
| Not done/not evaluable | 50 (22%) | 49 (21%) |